Predictors of Treatment Response in Late-onset Major Depressive Disorder

Aim and objectives: Predictors of treatment response may help to improve treatment approaches in late-onset major depression patients. The study will identify features of patients with major depression that may predict good and poor treatment response. It will use demographic, clinical, neuropsychological and brain MRI data to investigate the potential value of these as predictors of response to standard treatment over 12 weeks. For example, impairment of executive functioning on cognitive testing may predict patients whose depression does not respond to 12 weeks of treatment. MRI may reveal specific characteristics that predict good response to treatment. Methodology Subject inclusion and exclusion criteria Inclusion: Patients with major depressive disorder, diagnosed for the first time after the age of 60 years, with a Mini Mental State Examination score \>24/30. Exclusion: Participants with a history of other major psychiatric illness or intellectual disability will be excluded. Those who have unstable medical conditions, including a history of neurological disease (stroke, epilepsy, recent delirium, neurodegenerative disease or dementia) will also be excluded. Recruitment: Patients with late-onset major depressive disorder will be identified by members of care teams of the Mental Health of Older Adults Services of the South London and Maudsley NHS Foundation Trust. A poster and information leaflet about the study will be also provided to the services to facilitate recruitment. The researcher will also use the trust Consent for Contact (c4c)' mechanism to assist the recruitment process. Potential participants who contact the researcher or give their permission to be contacted will be sent a written brief information sheet and invited to respond via an expression of interest letter and a stamped and addressed envelope. If they are interested, a consent for screening and medical record review will be sought. And following screening for the absence of significant cognitive impairment with the Mini-Mental State Examination by the researcher if this has not already been performed, they will be provided with a full information sheet and be invited to consent to participate in the study at their home or the IOPPN depending on participants' preference. Screening assessment The initial screening assessment will be done at potential participants' residences. A brief history of psychiatric and medical conditions will be taken. Participants will be interviewed with the following assessments: * Mini-Mental State Examination (MMSE) is a 30 point assessment for general cognitive function, with exemption if they have been completed in clinical work within 1 month of the assessment. * MRI safety questionnaire If potential participants are eligible for inclusion into the study and remain interested, written information will be left with them and an appointment will be made for further discussion and gaining informed consent. If they are not eligible for the study on the basis of screening, or decide not to proceed at this stage, all data collected will be destroyed. Consent visit and baseline assessment: Subjects will have been encouraged to read all information sheets carefully and will have the opportunity to ask further questions at this stage. Their capacity to consent will be assessed by the researcher and they will then be asked to provide verbal and written consent to be involved in the study. The following baseline assessment and neuropsychological tests will be performed at participants' homes or the IOPPN depending on participants' preference and last about one and a half hour: 1. Demographic data including sex, age, marital and living status, number of education years completed, and occupation. 2. Clinical data including current prescribed medical treatment, current depressive episode onset and treatment type, dosage and duration received. 3. Cumulative Illness Rating Scale for Geriatrics (CIR-G) is a scoring questionnaire for assessing underlying medical disease. 4. Hospital Anxiety Depression Scale (HADS), a self-rating scale and Hamilton Depression Rating Scale (HAM-D 21 items), an interview-based rating scale are used for depressive severity assessment. 5. WHODAS 2.0 is a questionnaire assessing general functioning and disability. 6. Neuropsychological tests * Trail making test - a pen and paper based test for processing speed. * Digit span and Spatial Span tests - tests for working memory. * Verbal fluency, category fluency and design fluency - tests for fluency that ask participants to generate words or pictures in the rules given. * Colour-Word Interference test - a paper-based reading test for inhibition. A letter will be sent to participants' GPs to inform them of their participation. The GP may be asked to confirm or provide information in case of the participant has questionable medical history that might contraindicate an MRI procedure. MRI scan procedure: Participants will undergo an MRI scan at the CNS based at the IOPPN within 4 weeks of baseline assessment. A taxi will be provided for participants to travel to the IOPPN. At the CNS, participants will be encouraged to ask any questions and the MRI safety questionnaire will be repeated to ensure there are no contraindications. Noise protection will be provided to the participants and a mock scan will be offered to familiarize them with the real MRI scanner if they would like this. Participants will then undergo a structural and functional MRI scan, the latter includes asking them to close their eyes for a period of time. The MRI scan will last about 1 hour. After the MRI scan, transport by taxi will be provided to return participants to their home. Final assessment At Week 11, the researcher will contact the participants and make an appointment for the final assessment at Week 12 at their home or the IOPPN depending on participants' preference. The final assessment will last about one hour. Participants will undergo the same assessment as in baseline assessment and the Mini-Mental State Examination. Note that throughout and following the study, participants will receive standard care, following the Trust Care Pathway.